U.S. FDA warns Abbott Labs over heart device problems

(Reuters) - The U.S. Food and Drug Administration issued a warning letter to Abbott Laboratories, citing manufacturing flaws with a range of cardiovascular devices acquired with its purchase of St. Jude Medical in January for $25 billion.The letter, dated April 12 and made public on Thursday, sent Abbott's shares down 2 percent to $42.61.The FDA, which said the company failed to disclose at least one death associated with one of the devices, said an inspection of the company's facility in Sylmar